13F Holdings
中文EN

RARE Ultragenyx Pharmaceutical Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1515673 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY20.2%
TTM net income YoY-0.9%
TTM EPS YoY7.3%
Revenue 3-yr CAGR22.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-79.5%
Net margin-85.3%
FCF margin-70.1%
EBITDA margin-74.3%

Returns

ROE-656.6%
ROA-37.9%
ROIC (approx.)—
Asset turnover0.44x

Leverage & solvency

Liabilities / assets104.8%
Debt / equity—
Current ratio2.48x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$673.00M$560.00M$434.00M$363.33M$351.41M
R&D expense$750.00M$698.00M$648.00M$705.79M$497.15M
SG&A expense$349.00M$321.00M$310.00M$278.14M$219.98M
Operating income-$535.00M-$536.00M-$569.00M-$648.92M-$381.74M
Pretax income-$571.00M-$567.00M-$609.00M-$701.73M-$452.98M
Income tax$4.00M$2.00M-$2.00M$5.70M$1.04M
Net income-$575.00M-$569.00M-$607.00M-$707.42M-$454.02M
EBITDA-$500.00M-$500.00M-$543.00M-$630.70M-$368.50M
EPS (basic)-5.83-6.29-8.25-10.12-6.70
EPS (diluted)-5.83-6.29-8.25-10.12-6.70
Weighted avg. shares (diluted)98.60M90.50M73.50M69.91M67.80M
Balance sheet
Cash & equivalents$421.00M$174.00M$214.00M$132.94M$307.58M
Short-term investments$259.00M$436.00M$363.62M$614.82M$432.61M
Receivables$158.00M$122.00M$73.39M$40.45M$28.43M
Inventory$52.00M$45.00M$33.97M$26.77M$16.23M
Current assets$951.00M$817.00M$732.18M$883.90M$856.60M
PP&E, net$244.00M$266.00M$290.57M$259.73M$141.25M
Goodwill$44.00M$44.00M$44.41M$44.41M$44.41M
Intangibles$176.00M$178.00M$166.27M$160.10M$130.79M
Total assets$1.53B$1.50B$1.49B$1.55B$1.52B
Current liabilities$384.00M$344.00M$280.44M$261.21M$181.37M
Total liabilities$1.60B$1.24B$1.22B$1.19B$599.84M
Shareholders' equity-$80.00M$255.00M$275.00M$352.00M$922.56M
Shares outstanding96.60M92.50M82.32M70.20M69.34M
Cash flow statement
Operating cash flow-$466.00M-$414.00M-$475.00M-$380.46M-$338.69M
Capital expenditure$6.00M$7.00M$44.00M$116.12M$73.09M
Free cash flow-$472.00M-$421.00M-$519.00M-$496.59M-$411.79M
Investing cash flow$236.00M-$18.00M$168.00M-$291.65M-$195.37M
Financing cash flow$478.00M$399.00M$388.00M$501.21M$118.55M
Depreciation & amortization$35.00M$36.00M$26.00M$18.22M$13.24M
Stock-based compensation$153.00M$158.00M$135.00M$130.37M$104.98M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.